Document Detail

Applying the CONSORT and STROBE statements to evaluate the reporting quality of neovascular age-related macular degeneration studies.
MedLine Citation:
PMID:  19091408     Owner:  NLM     Status:  MEDLINE    
PURPOSE: To evaluate the quality of reporting in the neovascular age-related macular degeneration (nvAMD) literature by applying the Consolidated Standards for Reporting Trials (CONSORT) and Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement writing standards.
DESIGN: CONSORT and STROBE impact analysis; literature review.
PARTICIPANTS: Phase III randomized controlled trials (RCTs) of verteporfin photodynamic therapy, pegaptanib, and ranibizumab, and interventional case studies of bevacizumab for nvAMD.
METHODS: A literature search identified eligible articles published before October 31, 2007. We assessed the report quality of Phase III RCTs using the CONSORT statement and case series publications using the STROBE statement, both with indicators relevant to nvAMD.
MAIN OUTCOME MEASURES: Presence or absence of CONSORT or STROBE statement indicators.
RESULTS: Seven publications of Phase III RCTs and 29 publications on bevacizumab interventional case studies for nvAMD met our inclusion criteria. Of 37 possible CONSORT writing guideline items, the mean report quality for RCTs was 30.6 (83%), with a range from 23 to 35 (65%-95%). Of 35 possible STROBE writing guideline items, the mean report quality grade for intravitreal bevacizumab case series was 23 (70%), with a range from 16 to 31 (46%-94%). Among the bevacizumab studies, more than 90% reported scientific background, drug dose and administration, baseline characteristics, unadjusted results, and adverse events. Fewer than 20% reported study size calculations, handling of missing data, or a discussion of bias.
CONCLUSIONS: Since the adoption of the CONSORT standards by Ophthalmology and other journals in 1996, the reporting quality for RCTs has further improved among this cohort of nvAMD articles. On the other hand, no reporting standards for case series have existed until the recent publication of the STROBE statement. In this first application of the STROBE standards to ophthalmology, we found that the small interventional studies in our series had an average reporting score lower than the RCTs, but also that some individual scores were higher than the RCTs. This outcome demonstrates that good, useful articles can be written about small studies. Although not a direct measure of the quality of a study, good reporting allows a reader to assess the validity and applicability of the study's findings.
FINANCIAL DISCLOSURE(S): Proprietary or commercial disclosure may be found after the references.
Anne E Fung; Ram Palanki; Sophie J Bakri; Eric Depperschmidt; Andrea Gibson
Related Documents :
20956218 - Part 2: evidence evaluation and management of potential or perceived conflicts of inter...
18586178 - No consensus exists on search reporting methods for systematic reviews.
8607768 - Musculoskeletal and neuromuscular conditions of instrumental musicians.
20187938 - Applicability and generalisability of the results of systematic reviews to public healt...
7492238 - Distribution of cases of systemic lupus erythematosus at time of first symptom in an ur...
12945598 - Noma (cancrum oris) associated with oral myiasis in an adult.
Publication Detail:
Type:  Journal Article     Date:  2008-12-16
Journal Detail:
Title:  Ophthalmology     Volume:  116     ISSN:  1549-4713     ISO Abbreviation:  Ophthalmology     Publication Date:  2009 Feb 
Date Detail:
Created Date:  2009-02-03     Completed Date:  2009-02-13     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  7802443     Medline TA:  Ophthalmology     Country:  United States    
Other Details:
Languages:  eng     Pagination:  286-96     Citation Subset:  IM    
Pacific Eye Associates, California Pacific Medical Center, San Francisco, California 94115, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiogenesis Inhibitors / therapeutic use
Antibodies, Monoclonal / therapeutic use
Antibodies, Monoclonal, Humanized
Aptamers, Nucleotide / therapeutic use
Choroidal Neovascularization / etiology,  therapy*
Guidelines as Topic / standards
Macular Degeneration / complications,  therapy*
Ophthalmology / standards*
Periodicals as Topic / standards*
Photosensitizing Agents / therapeutic use
Porphyrins / therapeutic use
Publishing / standards*
Quality Control
Randomized Controlled Trials as Topic / standards*
Reg. No./Substance:
0/Angiogenesis Inhibitors; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Aptamers, Nucleotide; 0/Photosensitizing Agents; 0/Porphyrins; 0/pegaptanib; 0/ranibizumab; 129497-78-5/verteporfin; 2S9ZZM9Q9V/bevacizumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Quality of life in high myopia: implantable Collamer lens implantation versus contact lens wear.
Next Document:  Astigmatism in the Early Treatment for Retinopathy Of Prematurity Study: findings to 3 years of age.